-
Send to Friends (0)
Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3175)
All Articles published online
|
Publishing Process of This Article
|
Dec 21, 2021 (publication date) through Feb 5, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021; 27(47): 8069-8080 [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v27/i47/8069.htm |
| Number | Citing Articles |
| 1 |
Qiao Ke, Fuli Xin, Huipeng Fang, Yongyi Zeng, Lei Wang, Jingfeng Liu. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.913464
|
| 2 |
Qianyi Lin, Dexiong Chen, Kangde Li, Xiaomin Fan, Qi Cai, Weihong Lin, Chunhong Qin, Tao He. Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality Therapy. Frontiers in Radiology 2022; 2 doi: 10.3389/fradi.2022.858963
|
| 3 |
Renguo Guan, Chengyou Yu, Shaohua Li, Jie Mei, Wei Wei, Rongping Guo. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.998534
|
| 4 |
Jing-Nan Xue, Yan-Yu Wang, Yun-Chao Wang, Nan Zhang, Long-Hao Zhang, Zheng-Hui Lu, Li-Jin Zhao, Hai-Tao Zhao. Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary & Pancreatic Diseases International 2022; 21(5): 450 doi: 10.1016/j.hbpd.2022.08.014
|
| 5 |
Kang Chen, Cheng-Piao Luo, De-Xiang Ge, Ke-Lin Wang, Qin Luo, Yan-Zhi Li, Xue-Mei You, Bang-De Xiang, Le-Qun Li, Liang Ma, Jian-Hong Zhong. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.946693
|
| 6 |
Bowen Chen, Jin Lei, Haitao Zhao, Jinghui Dong, Zhen Zeng, Yinyin Li, Lingxiang Yu, Lin Zhou, Aiying Jia, Yinying Lu, Jiamin Cheng. Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. Journal of Hepatocellular Carcinoma 2022; : 1171 doi: 10.2147/JHC.S387254
|
| 7 |
Qingwei Zhu, Wei Rao, Junyu Huo, Zixiang Li, Song Wang, Wensheng Qiu, Ge Guan, Yang Xin, Ning Fan, Jinzhen Cai, Liqun Wu. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02661-2
|
| 8 |
Tatsuya Orimo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas. Annals of Surgical Oncology 2022; 29(13): 8436 doi: 10.1245/s10434-022-12495-z
|
| 9 |
Haoyang Bei, Weiheng Mai, Weifeng Chen, Mingyi Li, Yongguang Yang. Application of systemic treatment in conversion therapy options for liver cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.966821
|
| 10 |
Haowen Tang, Yinbiao Cao, Yiping Jian, Xuerui Li, Junfeng Li, Wenwen Zhang, Tao Wan, Zhe Liu, Wei Tang, Shichun Lu. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. BioScience Trends 2022; 16(2): 130 doi: 10.5582/bst.2022.01019
|